ライフサイエンスコーパス: ZFN

1 ZFN activity was dependent on the number of modules in e

2 ZFN-edited cells maintained both pluripotency and long-t

3 ZFN-induced double-strand breaks are subject to cellular

4 ZFN-mediated gene targeting yields high gene modificatio

5 ZFN-mediated site-specific mutagenesis and complete remo

6 ZFN-treated HSPCs retained the ability to engraft NOD/SC

7 ZFNs and TALENs enable a broad range of genetic modifica

8 ZFNs are chimeric proteins with significant potential fo

9 ZFNs are formed by fusing zinc-finger proteins to the no

10 ZFNs composed of six-finger MA arrays produced mutations

11 ZFNs directed against an eGFP transgene in Xenopus tropi

12 ZFNs directed against the noggin gene produced tadpoles

13 ZFNs engineered against the parasite gene pfcrt, respons

14 ZFNs recognizing the Arabidopsis ADH1 and TT4 genes were

15 ZFNs resulted from basic research on zinc finger protein

16 mbryos showed targeted changes in up to 33% (ZFNs) and 46% (TALENs) of blastocysts.

17 Soon afterwards, a ZFN-induced DSB was shown to stimulate homologous recomb

18 A second construct, containing a ZFN gene driven by the constitutive CsVMV promoter and a

19 g the catalytic activity of one monomer in a ZFN dimer.

20 We next introduced a ZFN into soybean via whole-plant transformation and gene

21 wever, application of these two methods to a ZFN pair targeted to the human CCR5 gene led to identifi

22 Using a ZFN that creates a double-strand break (DSB) at the endo

23 mine (Pyr)-susceptible Chesson strain with a ZFN plasmid carrying a Pyr-resistant mutant pvdhfr seque

24 lts broaden the therapeutic potential of AAV/ZFN-mediated genome editing in the liver and could expan

25 timal strategy for engineering highly active ZFNs is still unclear.

26 % of primary transgenics expressing the ADH1 ZFNs and 33% of transgenics expressing the TT4 ZFNs.

27 emonstrate reduced off-target activity after ZFN protein transduction relative to conventional delive

28 Transfer efficacy and ZFN activity were assessed in quantitative proof-of-conc

29 The donor DNA molecule and ZFN expression cassette were delivered into target plant

30 We observed that TALEN and ZFN have a reduced capability of secondary homing compar

31 trate for the first time that both TALEN and ZFN injected directly into pig zygotes can produce live

32 ta from CRISPR/Cas9 with those of TALENs and ZFNs and shows that efficiency of CRISPR/Cas9 is sixfold

33 Sequence-specific nucleases, such as ZFNs, TALE nucleases, and CRISPR/Cas9 have allowed the c

34 e for engineering context-dependent assembly ZFNs in the soybean genome.

35 describe complementary strategies to augment ZFN activity after gamma-retroviral transduction, includ

36 Because ZFNs can be designed against any locus, our data provide

37 Because ZFNs can potentially be engineered to digest a wide vari

38 LENs showed comparable activity to benchmark ZFNs, with allelic gene disruption frequencies of 15-30%

39 We used a modular assembly approach to build ZFNs that target the ROSA26 locus.

40 t, containing a GUS reporter gene flanked by ZFN cleavage sites, a GFP reporter gene and a PAT select

41 ansferase-encoding gene (hpt) was flanked by ZFN recognition sequences was constructed.

42 n (GFP) coding sequence (gfp) was flanked by ZFN recognition sequences was used to produce transgenic

43 reover, we measure the overhangs produced by ZFN cleavage and find that oligonucleotide donors with s

44 The mechanism of DSB by ZFNs requires (1) two ZFN monomers to bind to their adja

45 5' overhangs complementary to those made by ZFNs are efficiently ligated in vivo to the DSB.

46 diversity of genomic sequences targetable by ZFNs.

47 We show that macaque-specific CCR5 ZFNs efficiently induce CCR5 disruption at levels of up

48 In parallel, we constructed ZFNs from these cassettes and tested their ability to in

49 th a second plant expressing a corresponding ZFN gene.

50 aracteristics that can be tailored to create ZFNs with greater precision.

51 I cleavage domain for the creation of custom ZFNs with minimal cellular toxicity.

52 -in-one' lentiviral particles, we co-deliver ZFN proteins and the donor template for homology-directe

53 sent a versatile tool to transiently deliver ZFNs to human and mouse cells.

54 of safe and effective methods for delivering ZFNs into cells.

55 Cleavage is induced when two custom-designed ZFNs heterodimerize upon binding DNA to form a catalytic

56 By combining the use of designed ZFNs and commercial restriction enzymes, multiple plant

57 rgeted chromosomal locus, using two designed ZFNs.

58 e or greatly reduce the toxicity of designer ZFNs to human cells.

59 ne for beta-lactoglobulin (LGB) and detected ZFN-induced random mutations in 30% to 80% of embryos.

60 d the affinity of zinc fingers, we developed ZFNs specific for the TRAC locus that mediated 98% knock

61 ent cleavage of two loci using two different ZFN pairs.

62 NA sequences for cleavage by active, dimeric ZFNs.

63 , it remains challenging to design effective ZFNs for many genomic sequences using publicly available

64 density that approaches 1.0 (i.e., efficient ZFNs available for targeting almost every base step).

65 Co-injections of mRNAs encoding ZFNs targeting the second exon of monarch cry2 into "one

66 We used these residues to engineer ZFNs that have superior cleavage activity while suppress

67 and general method for converting engineered ZFNs into zinc finger nickases (ZFNickases) by inactivat

68 In this study, we sought to enhance ZFN-mediated targeted mutagenesis and gene targeting (GT

69 To improve the performance of existing ZFN technology, we developed an in vivo evolution-based

70 In contrast to cDNA expression, ZFN protein levels decline rapidly following internaliza

71 sign and in vitro conditions that facilitate ZFN-mediated homologous recombination.

72 ies on the mechanism of cleavage by 3-finger ZFNs established that the preferred substrates were pair

73 iable di-residues (RVDs) and 3- and 4-finger ZFNs, and validated 13 bona fide off-target sites for th

74 tforward modular assembly-based approach for ZFN construction and gene inactivation in zebrafish.

75 To assay for ZFN specificity, the authors generated human embryonic r

76 For ZFNs, this approach, combined with delivery of donors as

77 fold improvement in targeted mutagenesis for ZFNs containing derivatives of the Sharkey cleavage doma

78 rry an array of unique recognition sites for ZFNs and homing endonucleases and a family of modular sa

79 est strategies for the improvement of future ZFN design.

80 Using CoDA-generated ZFNs, we rapidly altered 20 genes in Danio rerio, Arabid

81 Heritable ZFN-induced lesions in two independent lines produced tr

82 sly published and newly selected heterodimer ZFN architectures.

83 bust editing by using obligate heterodimeric ZFNs engineered to minimize unwanted cleavage attributab

84 ed GUS and GFP, were crossed with homozygous ZFN plants, which expressed the ZFN gene.

85 Importantly, ZFN-driven gene correction in CD34(+) cells from the bon

86 More importantly, ZFN-mediated digestion of both donor and acceptor DNA mo

87 al application, simple methods that increase ZFN activity, thus ensuring genome modification, are hig

88 sely change the LGB sequence, we co-injected ZFNs or transcription activator-like effector nucleases

89 ts suggest that, when used appropriately, MA ZFNs are able to target more DNA sequences with higher s

90 268 array variants revealed that half of MA ZFNs of any array composition that exceed an ab initio B

91 However, many ZFNs display dose-dependent toxicity presumably due to t

92 Brain weights of Mecp2(ZFN/y) and Mecp2(ZFN/+ )rats were significantly reduced by postnatal day

93 eathing abnormalities were apparent in Mecp2(ZFN/y) rats, whereas Mecp2(ZFN/+ )rats displayed functio

94 ile females lacking one copy of Mecp2 (Mecp2(ZFN/+)) displayed a more protracted disease course.

95 Male rats lacking MeCP2 (Mecp2(ZFN/y)) were noticeably symptomatic as early as postnata

96 Brain weights of Mecp2(ZFN/y) and Mecp2(ZFN/+ )rats were significantly reduced

97 apparent in Mecp2(ZFN/y) rats, whereas Mecp2(ZFN/+ )rats displayed functional irregularities later in

98 We show that transferrin-mediated ZFN uptake leads to site-specific in situ cleavage of th

99 pecificities and nearly one-third of modular ZFNs generated lesions at their targets in the zebrafish

100 tudy, the authors report the design of novel ZFNs targeting the human rhodopsin gene.

101 ddresses these issues: zinc finger nuclease (ZFN) -mediated site-specific integration of therapeutic

102 -based gene targeting, zinc-finger nuclease (ZFN) and transcription activator-like effector nuclease

103 r nuclease (TALEN) and zinc finger nuclease (ZFN) can be engineered into site-specific synthetic self

104 transgene, flanked by zinc finger nuclease (ZFN) cleavage sites, was deleted from a stably transform

105 r nuclease (TALEN) and zinc finger nuclease (ZFN) genome editing technology enables site directed eng

106 The zinc finger nuclease (ZFN) mediated genomic editing generated a Tbc1d20 c.[418

107 ing electroporation of zinc finger nuclease (ZFN) mRNA with donor template delivery by adeno-associat

108 The emerging zinc finger nuclease (ZFN) technology facilitates gene targeting in diverse sp

109 The development of zinc finger nuclease (ZFN) technology has enabled the genetic engineering of t

110 This method uses a zinc-finger nuclease (ZFN) to create a site-specific double-strand break (DSB)

111 tly dysfunctional by a zinc-finger nuclease (ZFN)--is safe.

112 rgeted integration via zinc finger nuclease (ZFN)--mediated homologous recombination in A549 cells th

113 Initially, we injected zinc finger nuclease (ZFN)-encoding mRNA or DNA into bovine zygotes to verify

114 ces in transposon- and zinc finger nuclease (ZFN)-mediated gene knockout as well as the establishment

115 By combining zinc finger nuclease (ZFN)-mediated genome editing and iPSC technology, we pro

116 -mediated delivery of zinc finger nucleases (ZFN) proteins using transferrin receptor-mediated endocy

117 th no marker gene via zinc finger nucleases (ZFN) technology.

118 Here we used designer nucleases (ZFNs, TALENs, and CRISPR/Cas9) to introduce DSBs on two

119 Zinc-finger nucleases (ZFNs) allow targeted gene inactivation in a wide range o

120 donucleases including zinc finger nucleases (ZFNs) and clustered regularly interspaced short palindro

121 V) vector delivery of zinc finger nucleases (ZFNs) and corrective donor template to the predominantly

122 ination of engineered zinc finger nucleases (ZFNs) and homing endonucleases.

123 that a combination of zinc finger nucleases (ZFNs) and piggyBac technology in human iPSCs can achieve

124 le the specificity of zinc-finger nucleases (ZFNs) and RNA-guided endonucleases has been assessed to

125 Zinc-finger nucleases (ZFNs) and TAL effector nucleases (TALENs) have been show

126 nucleases, including zinc finger nucleases (ZFNs) and TAL effector nucleases (TALENs), have made it

127 applicable with both zinc finger nucleases (ZFNs) and Tale nucleases (TALENs), and has enabled us to

128 Zinc finger nucleases (ZFNs) and transcription activator-like effector nuclease

129 This study optimized zinc-finger nucleases (ZFNs) and transcription activator-like effector nuclease

130 icable strategy using zinc finger nucleases (ZFNs) and transcription activator-like effector nuclease

131 ected nucleases, like zinc-finger nucleases (ZFNs) and transcription activator-like effector nuclease

132 Zinc-finger nucleases (ZFNs) and transcription activator-like effector nuclease

133 Zinc finger nucleases (ZFNs) are engineered restriction enzymes designed to tar

134 Zinc-finger nucleases (ZFNs) are important tools for genome engineering.

135 Zinc-finger nucleases (ZFNs) are powerful tools for editing the genomes of cell

136 Zinc finger nucleases (ZFNs) are powerful tools for gene therapy and genetic en

137 Engineered zinc-finger nucleases (ZFNs) are promising tools for genome manipulation, and d

138 Zinc-finger nucleases (ZFNs) are targetable DNA cleavage reagents that have bee

139 Zinc-finger nucleases (ZFNs) are versatile reagents that have redefined genome

140 Using zinc-finger nucleases (ZFNs) designed to flank the sickle mutation, we demonstr

141 Zinc-finger nucleases (ZFNs) drive efficient genome editing by introducing a do

142 Zinc-finger nucleases (ZFNs) drive highly efficient genome editing by generatin

143 Engineered zinc-finger nucleases (ZFNs) enable targeted genome modification.

144 Zinc finger nucleases (ZFNs) facilitate tailor-made genomic modifications in vi

145 e the use of designed zinc finger nucleases (ZFNs) for efficient transgenesis without drug selection

146 The widespread use of zinc-finger nucleases (ZFNs) for genome engineering is hampered by the fact tha

147 rand breaks (DSBs) by zinc finger nucleases (ZFNs) has been deployed for gene replacement in plant ce

148 The development of zinc finger nucleases (ZFNs) has permitted efficient genome editing in transfor

149 Zinc-finger nucleases (ZFNs) have been used for genome engineering in a wide va

150 Zinc-finger nucleases (ZFNs) have emerged as powerful tools for delivering a ta

151 Zinc-finger nucleases (ZFNs) have enabled highly efficient gene targeting in mu

152 jection of engineered zinc-finger nucleases (ZFNs) in embryos was used to generate gene knockouts in

153 Engineered zinc finger nucleases (ZFNs) induce DNA double-strand breaks at specific recogn

154 via microinjection of zinc-finger nucleases (ZFNs) into fertilized eggs.

155 A pair of zinc finger nucleases (ZFNs) or transcription activator-like effector nucleases

156 ble reagents were the zinc finger nucleases (ZFNs) showing that arbitrary DNA sequences could be addr

157 e extensively studied zinc finger nucleases (ZFNs) targeting C-C chemokine receptor type 5.

158 ng the specificity of zinc finger nucleases (ZFNs) that engineers the FokI catalytic domain with the

159 f this parasite using zinc-finger nucleases (ZFNs) that produce a double-strand break in a user-defin

160 We designed zinc-finger nucleases (ZFNs) that promoted the disruption of endogenous TCR bet

161 sion of CCR5-targeted zinc finger nucleases (ZFNs) to generate CCR5-negative cells, which could then

162 feasibility of using zinc-finger nucleases (ZFNs) to knock out a gene directly in a pure NOD backgro

163 iled macaque HSPCs by zinc finger nucleases (ZFNs) was feasible.

164 off-target effects of zinc finger nucleases (ZFNs) were described-one using an in vitro cleavage site

165 Novel zinc finger nucleases (ZFNs) were designed to target the human rhodopsin gene a

166 in the monarch using zinc-finger nucleases (ZFNs), engineered nucleases that generate mutations at t

167 ld-type CC-125) using zinc-finger nucleases (ZFNs), genetically encoded CRISPR/associated protein 9 (

168 igner nucleases, like zinc-finger nucleases (ZFNs), represent valuable tools for targeted genome edit

169 ses or meganucleases, zinc-finger nucleases (ZFNs), TAL effector nucleases (TALENs), and CRISPR-assoc

170 pioneering work using zinc-finger nucleases (ZFNs), to the advent of the versatile and specific TALEN

171 nucleases, including zinc-finger nucleases (ZFNs), transcription activator-like (TAL) effector nucle

172 le cleavage reagents: zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (

173 hree central methods, zinc finger nucleases (ZFNs), transcription activator-like effectors (TALENs),

174 Using engineered zinc-finger nucleases (ZFNs), we disrupted CCR5 in human CD34(+) hematopoietic

175 cision targeting with zinc-finger nucleases (ZFNs), we have developed an expanded set of architecture

176 mbryonic injection of zinc-finger nucleases (ZFNs), which generate site-specific double strand breaks

177 his organism, we used zinc-finger nucleases (ZFNs), which take advantage of homology-directed DNA rep

178 gulated expression of zinc finger nucleases (ZFNs)-enzymes engineered to create DNA double-strand bre

179 y genome editing with zinc-finger nucleases (ZFNs).

180 y and precision as do zinc-finger nucleases (ZFNs).

181 cine max) genes using zinc-finger nucleases (ZFNs).

182 nucleases (TALENs) or zinc-finger nucleases (ZFNs).

183 However, the high frequency of observed ZFN-induced mutagenesis suggests that targeted mutations

184 Here, we show that in silico abstraction of ZFN cleavage profiles obtained from in vitro cleavage si

185 of ZFNs, we compared the in vivo activity of ZFN variants targeting the zebrafish kdrl locus, which d

186 ficacy of CoDA will enable broad adoption of ZFN technology and make possible large-scale projects fo

187 We report here the successful application of ZFN pairs to specifically and efficiently knock out Tnfr

188 ur study demonstrates a novel application of ZFN technology to the targeted genetic engineering of hu

189 ere, we describe a large-scale comparison of ZFN and TALEN mutagenicity in zebrafish.

190 the expression, purification and delivery of ZFN proteins, which are intrinsically cell-permeable; TA

191 ized, uncontrolled study of a single dose of ZFN-modified autologous CD4 T cells.

192 onally, despite the much shorter duration of ZFN activity, the efficiency of gene correction approach

193 as employed to investigate the efficiency of ZFN mutagenesis at each target locus.

194 High efficiency of ZFN-mediated targeted integration was achieved in both h

195 s recombination and an absolute frequency of ZFN-directed homologous recombination as high as 17% in

196 eport the quantification of the frequency of ZFN-mediated homologous recombination.

197 This article briefly reviews the history of ZFN development and summarizes applications that have be

198 gs establish an energy compensation model of ZFN specificity in which excess binding energy contribut

199 By co-packaging pairs of ZFN proteins with donor RNA in 'all-in-one' lentiviral p

200 hould enable more comprehensive profiling of ZFN specificities.

201 ting finger archives and expand the range of ZFN-accessible sequences threefold.

202 Comparative studies of ZFN activity in a predetermined target locus and a known

203 lly, we successfully tracked the survival of ZFN-edited human embryonic stem cells and their differen

204 s in murine models, demonstrating the use of ZFN-edited cells for preclinical studies in regenerative

205 break repair limit the scope and utility of ZFN-initiated events.

206 ent cleavage domain will aid in a variety of ZFN applications in medicine and biology.

207 ed partly substantial off-target activity of ZFNs targeting CCR5 and AAVS1 at six known and five nove

208 To facilitate the application of ZFNs within the zebrafish community we constructed a pub

209 bright prospects for future applications of ZFNs, including human gene therapy, are discussed.

210 Here we discuss the architecture of ZFNs and strategies for generating targeted modification

211 The modular architecture of ZFNs and TALENs allows for the rapid design of novel SSE

212 In the case of ZFNs fused to wild-type FokI cleavage domains, homodimer

213 rchitecture and show that direct delivery of ZFNs as proteins leads to efficient endogenous gene disr

214 ique to enhance the experimental efficacy of ZFNs.

215 Injection of ZFNs resulted in a range of specific gene deletions, fro

216 The modular assembly (MA) of ZFNs from publicly available one-finger archives provide

217 Pronuclear microinjection of ZFNs, shown by our data to be an efficient and rapid met

218 Four pairs of ZFNs incorporating these ZFAs generated targeted lesions

219 n, we highlight the therapeutic potential of ZFNs and TALENs and discuss future prospects for the fie

220 this could limit the efficacy and safety of ZFNs by inducing off-target cleavage.

221 rs influencing the functional specificity of ZFNs, we compared the in vivo activity of ZFN variants t

222 We also discover that one subunit of ZFNs and one subunit of TALENs can form a pair of hybrid

223 A suite of ZFNs were engineered by the recently described context-d

224 d provides a proof of concept for the use of ZFNs for manipulating genes in the monarch butterfly gen

225 ds, and since our cloning system is based on ZFN and homing endonucleases, it may be possible to reco

226 matic study on the effect of array length on ZFN activity.

227 previously been proposed to predict optimal ZFN and TALEN target sites did not predict mutagenicity

228 th of recognition DNA sequences by TALENs or ZFNs does not necessarily translate to a higher efficien

229 We focused our ZFN approach on targeting the type 2 vertebrate-like cry

230 utilized in future studies to further refine ZFNs through cooperative specificity.

231 d by the simultaneous action of two separate ZFN pairs.

232 Since ZFNs can be designed to bind and cleave a wide range of

233 gp) was generated using a rat Mdr1a-specific ZFN.

234 Specific ZFNs targeting dicer-like (DCL) genes and other genes in

235 Using the CCR5-specific ZFNs as a model system, we show that introduction of a n

236 t quantification of these rhodopsin-specific ZFNs to induce a targeted double-strand break in the hum

237 However, construction of target-specific ZFNs is technically challenging.

238 and robustly increased the level of stable, ZFN-induced gene disruption, thereby providing a simple

239 ell-penetrating capabilities of the standard ZFN architecture and show that direct delivery of ZFNs a

240 ess binding energy contributes to off-target ZFN cleavage and suggest strategies for the improvement

241 Tbc1d20 (ZFN/ZFN) males are infertile and the analysis of the sem

242 formation, thus establishing bs and Tbc1d20 (ZFN/ZFN) as allelic variants.

243 gy remains unclear, both the bs and Tbc1d20 (ZFN/ZFN) mice are excellent model organisms for future s

244 The compound heterozygote Tbc1d20 (ZFN/bs) mice, generated from an allelic bs/+ X Tbc1d20 (

245 The evaluation of Tbc1d20 (ZFN/ZFN) eyes identified severe cataracts and thickened

246 e, generated from an allelic bs/+ X Tbc1d20 (ZFN/+) cross, exhibited cataracts and aberrant acrosomal

247 426del] deletion encoding a putative TBC1D20-ZFN protein with an in-frame p.[H140_Y143del] deletion w

248 ce an average of 10-fold more mutations than ZFNs.

249 We conclude that ZFN technology is an efficient and convenient alternativ

250 These findings indicate that ZFN-based mutagenesis provides an efficient method for m

251 The fact that ZFNs and TALENs have been used for genome modification o

252 Here, we report that ZFNs can be engineered to induce a site-specific DNA sin

253 Here we show that ZFNs are able to induce DSBs efficiently when delivered

254 etions (1-142 bp) that were localized at the ZFN cleavage site and likely derived from imprecise repa

255 exhibited somatic mutations localized at the ZFN target sites for seven out of nine targeted genes.

256 y-independent targeted gene insertion at the ZFN-specified locus.

257 h homozygous ZFN plants, which expressed the ZFN gene.

258 e or both zinc-finger proteins (ZFPs) in the ZFN dimer, as well as the option to skip bases between t

259 tem designed to functionally interrogate the ZFN dimer interface.

260 eral insights into the implementation of the ZFN technology.

261 owed efficient heritable transmission of the ZFN-induced mutation in the subsequent generation.

262 se event was associated with infusion of the ZFN-modified autologous CD4 T cells and was attributed t

263 n together, our studies demonstrate that the ZFN-generated Mdr1a(-/-) rat will be a valuable tool for

264 isruption of Mdr1a and demonstrated that the ZFN-mediated modifications lead to true knockouts.

265 of which were genetically modified with the ZFN.

266 The ZFNs directed gene addition to the ROSA26 locus, which e

267 The ZFNs were active in a variety of cell types in a time- a

268 lls, albeit at a lower frequency than by the ZFNs from which they were derived.

269 vage attributable to homodimerization of the ZFNs.

270 These ZFN architectures provide a general means for obtaining

271 These ZFNs are a promising resource for cell engineering, mous

272 These ZFNs may be useful for the treatment of retinal diseases

273 ndependently influence the fidelity of these ZFNs.

274 ep sequencing technology, we show that these ZFNs are highly specific for the CCR5 locus in primary c

275 For three ZFN pairs, we engineered single-residue substitutions in

276 Thus, ZFN-driven gene correction can be achieved in vivo, rais

277 life cycle and produced vectors to transfer ZFNs in the form of protein, mRNA and episomal DNA.

278 treatments can be evaluated by transplanting ZFN-treated HSPC into immunodeficient mice, where the ex

279 The ADH1 and TT4 ZFNs were placed under control of an estrogen-inducible

280 seedlings induced to express the ADH1 or TT4 ZFNs exhibited somatic mutation frequencies of 7% or 16%

281 Ns and 33% of transgenics expressing the TT4 ZFNs.

282 he mechanism of DSB by ZFNs requires (1) two ZFN monomers to bind to their adjacent cognate sites on

283 genome, that can be cleaved in vitro by two ZFNs: CCR5-224 and VF2468, which target the endogenous h

284 Unlike ZFNs and TALENs that use protein motifs for DNA sequence

285 Here we use ZFN technology in embryos to introduce sequence-specific

286 expression of endogenous cyclin D1, we used ZFN technology to insert a secreted luciferase reporter

287 We used ZFN technology to integrate a construct containing monom

288 f reporting endogenous gene activities using ZFN technology could be applied to other cancer targets.

289 Using ZFNs specific to the gene encoding P. vivax dihydrofolat

290 Using ZFNs, genes were edited in a reliable, predictable manne

291 knockouts in a pure NOD background by using ZFNs without potential confounding factors introduced by

292 by loss of SMC6B was further confirmed using ZFNs that target two other Arabidopsis genes, namely, TT

293 We observed improved efficiency using ZFNs, TALENs, two CRISPR/Cas9, and CRISPR/Cas9 nickase t

294 ty, and identified germ line mutations using ZFNs whose somatic mutations rates are well below the co

295 animals, and cell-based therapies utilizing ZFNs are undergoing clinical trials.

296 In vitro, ZFNs have been shown to promote efficient genome editing

297 at a target locus, but it is unclear whether ZFNs can induce DSBs and stimulate genome editing at a c

298 In contrast, mice transplanted with ZFN-modified HSPCs underwent rapid selection for CCR5(-/

299 simple ssDNA oligonucleotides in tandem with ZFNs to efficiently produce human cell lines with three

300 Lymphocytes treated with ZFNs lacked surface expression of CD3-TCR and expanded w